Navigation Links
Amira Pharmaceuticals Announces the Nomination of an Orally Available Pre-Clinical Candidate in a New LPA-Related Program, an Autotaxin Inhibitor
Date:12/15/2010

SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Amira Pharmaceuticals, Inc. announced today that it has successfully identified a novel pre-clinical candidate for its newest lysophosphatidic acid (LPA)-related program, autotaxin.  Autotaxin is an enzyme upstream from LPA receptors and has been implicated in a number of diseases including rheumatoid arthritis, glioblastoma, lung, breast, ovarian and thyroid cancers.

"We are pleased to announce that we have identified an orally bioavailable and highly selective autotaxin inhibitor," said Peppi Prasit, Ph.D., Chief Scientific Officer.  "Previous published data implicates autotaxin as a potent stimulator of tumor cell motility.  Cells over expressing autotaxin result in amplified tumorigenesis and metastatic potential.  These observations when combined with our recent pre-clinical experiments, which demonstrated that an autotaxin-specific inhibitor can successfully inhibit tumor metastases, are quite exciting."

Bob Baltera, Chief Executive Officer added, "As we have stated before, we are committed to exploring the science and medicine related to the LPA pathway.  We believe there are numerous potential drug targets in this pathway, and our autotaxin inhibitor is the latest in our portfolio of LPA-related drug targets, which also includes our LPA1 receptor antagonist AM152 which is currently in phase 1 clinical trials.  While a great deal of work remains in advancing the autotaxin program to the clinic, we look forward to communicating our progress in 2011."

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and development of new drugs to treat inflammatory disease.  Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, fibrotic diseases and cancer.  Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.  For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Pharmaceuticals Announces Initiation of Phase I Clinical Trial for AM152, A Novel LPA1 Antagonist
2. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
3. Amira Pharmaceuticals Named One of Most Promising Biotech Companies by FierceBiotechs Annual Fierce 15
4. Visage Imaging Releases Amira 5.3
5. Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
6. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
7. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
8. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
9. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
10. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
11. Anthera Pharmaceuticals Selects the Merck BioManufacturing Network as Manufacturing Supplier for A-623, Antheras Investigational Novel Peptibody Agent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... , Feb. 21, 2017 Diabetic Shoes Market: ... ... can be described as a disease, which is marked by ... production and insulin action. The disease has become a global ... death. Diabetes affects several organs of the body including eyes, ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
(Date:2/21/2017)... Ky. , Feb. 21, 2017 ... imaging leader, today announced a new imaging solution that connects ... Solarity® platform, one of the world,s leading scanning and ... The Solarity Connector enables hospitals to use a Lexmark ... information into the Solarity workflow, helping facilities reach ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... February 21, 2017 , ... ... senior director at PolicyLink, will be the keynote speaker at its second Professional ... Men of Color Framework, which develops comprehensive strategies to create and expand opportunities ...
(Date:2/21/2017)... ... February 21, 2017 , ... Individuals who ... directly related to surgery, treatment, therapy and management. Regular exercise in proper environments ... of life despite their diseases. On February 23, 2017, 1:00-2:00 p.m. E.S.T., a ...
(Date:2/21/2017)... ... February 21, 2017 , ... American Veterinarian™, the premier ... be launching its first bi-monthly issue of 2017 in February. The inaugural issue ... and One Health. , In making the announcement, American Veterinarian™ Publisher Chris ...
(Date:2/21/2017)... ... February 21, 2017 , ... Atlanta-based ... predictive analytic firm Predixion’s Healthcare IT practice. Predixion, which raised $42M+ to date, ... by giants including Accenture, GE Ventures, and Software AG , will bring ...
(Date:2/21/2017)... ... ... A February 6 article on Healio describes a recent review ... treatments have led to significant improvements in weight loss and other health outcomes resulting ... very few problematic results relating to the treatment. Beverly Hills Physicians (BHP) says that ...
Breaking Medicine News(10 mins):